Navigation Links
Questcor Pharmaceuticals Selects BDO USA as its Auditor
Date:3/4/2011

ANAHEIM, Calif., March 4, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) has completed a formal selection process and appointed BDO USA, LLP ("BDO") as its independent, registered public accounting firm for the auditing of Questcor's consolidated financial statements.  Questcor has selected BDO to replace Odenberg Ullakko Muranishi & Co. LLP ("OUM") as its independent registered public accounting firm.

"As we continue our strategy to grow through increased sales of Acthar, we believe that BDO will provide Questcor and its stakeholders with the highest levels of assurance services for our financial accounting, reporting and compliance requirements," said Don M. Bailey, President and CEO of Questcor. "We appreciate the efforts and professionalism of the team at Odenberg Ullakko Muranishi & Co. during the past 6 years."

During the period in which OUM was engaged with Questcor, there were no disagreements between OUM and Questcor on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. If there had been such disagreements, OUM would have been compelled to disclose the nature of the disagreements with its reports. The reports of OUM on the consolidated financial statements of the Company did not contain any adverse opinion or disclaimer of opinion. These reports have not been qualified or modified as to uncertainty, audit scope or accounting principles.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age.  Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports 2010 Financial Results
2. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
3. Questcor Pharmaceuticals Reports Strong Finish to 2010
4. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
5. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. Questcor to Present at the Maxim Group Growth Conference
7. Questcor Reports Third Quarter 2010 Results
8. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
11. Questcor to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... SEATTLE , Jan. 24, 2017  CTI BioPharma ... that Michael A. Metzger has been appointed ... experience leading and growing companies in the biopharmaceutical industry ... pleased to welcome Michael to the Board of CTI ... CEO of CTI BioPharma. "Michael is an accomplished leader ...
(Date:1/24/2017)... 24, 2017 When tragedy strikes, victims often can,t communicate, ... conditions they have, and who back home is wondering about them. ... informed about the safety of their family and friends, while helping ... in times of crisis. ... If you find yourself or your family in one of ...
(Date:1/24/2017)... 24, 2017 Trifecta Clinical , a ... appointing Rick Ward to Vice President of ... is also announcing the promotion of Ericka Atkinson ... Rick joins Trifecta from Greenphire where he ... senior business development positions within the healthcare industry throughout ...
Breaking Medicine Technology:
(Date:1/24/2017)... Santa Rosa, California (PRWEB) , ... January 24, 2017 , ... ... named Cary McNamara as chief financial officer. , “Cary’s broad financial ... individual who possesses both the strategic planning and day-to-day financial operations skills we need ...
(Date:1/24/2017)... ... January 24, 2017 , ... The Cruise Web ... as part of the line’s 4th Annual MSC True Partnerships’ Awards. , ... American travel partners for the year based on overall business growth in revenue and ...
(Date:1/24/2017)... Baltimore, MD (PRWEB) , ... January 24, 2017 ... ... applicants to advance to the semi-final round of the 2017 Cupid's Cup Entrepreneurship ... competition celebrates its 12th year in 2017. The entrepreneurs will showcase their businesses ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health ... annual Solutions Series of webinars will start January 31 with a session about ... of current health and benefits topics, including employee engagement, pricing transparency, population health ...
(Date:1/24/2017)... ... , ... His message has been heard by more than 100,000 students and ... , Joel Feldman, has reached his biggest national audience yet: the three million daily ... newspapers in circulation in the country, and he hopes it will help spread his ...
Breaking Medicine News(10 mins):